Search

Your search keyword '"Emanuela Abiusi"' showing total 2 results
Start Over Author "Emanuela Abiusi" Journal elife
2 results on '"Emanuela Abiusi"'

1. SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples

Author

Emanuela Abiusi, Paola Infante, Cinzia Cagnoli, Ludovica Lospinoso Severini, Marika Pane, Giorgia Coratti, Maria Carmela Pera, Adele D'Amico, Federica Diano, Agnese Novelli, Serena Spartano, Stefania Fiori, Giovanni Baranello, Isabella Moroni, Marina Mora, Maria Barbara Pasanisi, Krizia Pocino, Loredana Le Pera, Davide D'Amico, Lorena Travaglini, Francesco Ria, Claudio Bruno, Denise Locatelli, Enrico Silvio Bertini, Lucia Ovidia Morandi, Eugenio Mercuri, Lucia Di Marcotullio, and Francesco Danilo Tiziano

Subjects
spinal muscular atrophy, mRNA, miRNA, biomarker, SMN1, skeletal muscle, Medicine, Science, Biology (General), QH301-705.5
Abstract

Background: Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by the degeneration of the second motor neuron. The phenotype ranges from very severe to very mild forms. All patients have the homozygous loss of the SMN1 gene and a variable number of SMN2 (generally 2–4 copies), inversely related to the severity. The amazing results of the available treatments have made compelling the need of prognostic biomarkers to predict the progression trajectories of patients. Besides the SMN2 products, few other biomarkers have been evaluated so far, including some miRs. Methods: We performed whole miRNome analysis of muscle samples of patients and controls (14 biopsies and 9 cultures). The levels of muscle differentially expressed miRs were evaluated in serum samples (51 patients and 37 controls) and integrated with SMN2 copies, SMN2 full-length transcript levels in blood and age (SMA-score). Results: Over 100 miRs were differentially expressed in SMA muscle; 3 of them (hsa-miR-181a-5p, -324-5p, -451a; SMA-miRs) were significantly upregulated in the serum of patients. The severity predicted by the SMA-score was related to that of the clinical classification at a correlation coefficient of 0.87 (p

Published
2021
Full Text
View/download PDF

2. SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples

Author

Adele D'Amico, Lucia Morandi, Eugenio Mercuri, Lorena Travaglini, Francesco Danilo Tiziano, Maria Barbara Pasanisi, Ludovica Lospinoso Severini, Denise Locatelli, Paola Infante, Giovanni Baranello, Enrico Bertini, Agnese Novelli, Giorgia Coratti, Francesco Ria, Loredana Le Pera, Claudio Bruno, Isabella Moroni, Stefania Fiori, Cinzia Cagnoli, Marika Pane, Lucia Di Marcotullio, Davide D'Amico, Maria Carmela Pera, Krizia Pocino, Emanuela Abiusi, Federica Diano, Serena Spartano, and Marina Mora

Subjects
Male, Pathology, Mouse, SMN1, Settore MED/03 - GENETICA MEDICA, Pathogenesis, Medicine, genetics, Biology (General), Child, spinal muscular atrophy, General Neuroscience, Skeletal, General Medicine, Middle Aged, SMA, Muscular Atrophy, medicine.anatomical_structure, Child, Preschool, Muscle, Biomarker (medicine), biomarker, Female, Research Article, Human, Adult, medicine.medical_specialty, Spinal, Adolescent, QH301-705.5, Science, mRNA, General Biochemistry, Genetics and Molecular Biology, miRNA, skeletal muscle, Muscular Atrophy, Spinal, Settore MED/39 - NEUROPSICHIATRIA INFANTILE, Settore MED/04 - PATOLOGIA GENERALE, microRNA, genomics, Humans, Preschool, Muscle, Skeletal, General Immunology and Microbiology, business.industry, Skeletal muscle, Infant, Genetics and Genomics, Spinal muscular atrophy, Motor neuron, medicine.disease, MicroRNAs, business, Transcriptome, Biomarkers
Abstract

Background:Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by the degeneration of the second motor neuron. The phenotype ranges from very severe to very mild forms. All patients have the homozygous loss of the SMN1 gene and a variable number of SMN2 (generally 2–4 copies), inversely related to the severity. The amazing results of the available treatments have made compelling the need of prognostic biomarkers to predict the progression trajectories of patients. Besides the SMN2 products, few other biomarkers have been evaluated so far, including some miRs.Methods:We performed whole miRNome analysis of muscle samples of patients and controls (14 biopsies and 9 cultures). The levels of muscle differentially expressed miRs were evaluated in serum samples (51 patients and 37 controls) and integrated with SMN2 copies, SMN2 full-length transcript levels in blood and age (SMA-score).Results:Over 100 miRs were differentially expressed in SMA muscle; 3 of them (hsa-miR-181a-5p, -324-5p, -451a; SMA-miRs) were significantly upregulated in the serum of patients. The severity predicted by the SMA-score was related to that of the clinical classification at a correlation coefficient of 0.87 (p-5).Conclusions:miRNome analyses suggest the primary involvement of skeletal muscle in SMA pathogenesis. The SMA-miRs are likely actively released in the blood flow; their function and target cells require to be elucidated. The accuracy of the SMA-score needs to be verified in replicative studies: if confirmed, its use could be crucial for the routine prognostic assessment, also in presymptomatic patients.Funding:Telethon Italia (grant #GGP12116).

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results